Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)

Last updated: June 1, 2018
Sponsor: Cytori Therapeutics
Overall Status: Completed

Phase

N/A

Condition

Raynaud's Disease

Scleroderma

Lupus

Treatment

N/A

Clinical Study ID

NCT02396238
STAR Trial
  • Ages 18-70
  • All Genders

Study Summary

The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  1. Males or females ≥ 18 and ≤ 70 years of age

  2. Diagnosis of diffuse cutaneous scleroderma (duration > 5 years) or limited cutaneousscleroderma.

  3. Cochin score ≥ 20 units

  4. Ability to safely undergo liposuction

  5. Symptoms consistent with Raynaud's Phemomena

  6. Compliant with standard preventative recommendations

Exclusion

Key Exclusion Criteria:

  1. Body Mass Index < 18 kg/m2

  2. Active infection in any finger during screening period or infection in any fingerrequiring antibiotics in the 30 days prior to the Screening Visit

  3. Active infection at the potential site(s) of fat harvest during the screening period

  4. Contractures of any finger or ulceration at point of injection precluding completionof injection procedure

  5. Amputation of any finger proximal to the proximal interphalangeal joint or anyamputation in more than one finger

  6. Diagnosis of Rheumatoid Arthritis

  7. Inflammatory arthritis of the hand, including significant osteoarthritis, that is notdue to scleroderma or significant acute inflammation in the hand that is due toscleroderma, as per the investigator's clinical judgment

  8. Oral cyclophosphamide exceeding 2 mg/kg/day, any intravenous cyclophosphamide,methotrexate exceeding 25 mg/week, mycophenolate mofetil exceeding 3 gm/day,hydoxychloroquine exceeding 7 mg/kg/day or azathioprine exceeding 300 mg/day or anyother immunosuppressive medication in the 90 days prior to the Screening Visit

Study Design

Total Participants: 88
Study Start date:
May 15, 2015
Estimated Completion Date:
May 22, 2018

Study Description

The STAR Trial is a prospective, randomized, multi-center device trial intended to assess safety and efficacy of subcutaneous administration of Celution processed ADRCs into fingers of patients with hand dysfunction due to scleroderma.

Following informed consent and screening evaluations, eligible subjects will undergo pre-operative testing. Subjects will then undergo fat harvest through small volume liposuction under local anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs for immediate subcutaneous administration under local anesthesia. Subjects will be randomly assigned to receive ADRCs (40 million cells) or a visually-matched placebo in a 1:1 ratio. All subjects will receive subcutaneous administration of test substance (ADRC or placebo) into all fingers of both hands. Following completion of all 48 week visits and database lock, placebo treated subjects will be offered treatment with their ADRCs cells should they continue to qualify according to the inclusion/exclusion criteria and should they wish to be treated with ADRCs and agree to the fat harvest procedure.

Connect with a study center

  • Arizona Arthritis and Rheumatology Research, PLLC

    Phoenix, Arizona 85253
    United States

    Site Not Available

  • Baptist Health Center for Clinical Research

    Little Rock, Arkansas 72205
    United States

    Site Not Available

  • Arthritis Associates of Southern California

    Los Angeles, California 90045
    United States

    Site Not Available

  • UCLA David Geffen School of Medicine

    Los Angeles, California 90095
    United States

    Site Not Available

  • Georgetown University Hospital

    Washington, District of Columbia 20007
    United States

    Site Not Available

  • Northwestern University

    Chicago, Illinois 60611
    United States

    Site Not Available

  • Heartland Research Associates

    Wichita, Kansas 67207
    United States

    Site Not Available

  • Central Kentucky Research Associates, Inc.

    Lexington, Kentucky 40509
    United States

    Site Not Available

  • Johns Hopkins University

    Baltimore, Maryland 21224
    United States

    Site Not Available

  • Boston University Medical Center

    Boston, Massachusetts 02118
    United States

    Site Not Available

  • University of Michigan

    Ann Arbor, Michigan 48109
    United States

    Site Not Available

  • West Michigan Rheumatology, PLLC

    Grand Rapids, Michigan 49546
    United States

    Site Not Available

  • Center For Pharmaceutical Research

    Kansas City, Missouri 64114
    United States

    Site Not Available

  • Robert Wood Johnson Medical School

    New Brunswick, New Jersey 08901
    United States

    Site Not Available

  • Hospital for Special Surgery

    New York, New York 10021
    United States

    Site Not Available

  • Duke University Medical Center

    Durham, North Carolina 27710
    United States

    Site Not Available

  • Cleveland Clinic

    Cleveland, Ohio 44195
    United States

    Site Not Available

  • University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

  • University of Pittsburgh

    Pittsburgh, Pennsylvania 15261
    United States

    Site Not Available

  • University of Texas Houston Medical School

    Houston, Texas 77030
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.